Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK/PD and long-term safety study of benralizumab in children with severe eosinophilic asthma
jRCT2080225211Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of benralizumab in eosinophilic asthma (EA) (2 cohorts), sponsored by AstraZeneca. Started May 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT2080225211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225211.